Propofol attenuates pain hypersensitivity and neuroinflammation in chronic constriction injury rats by regulating miR-1249-3p/VEGFA axis Authors: Hailin Zhao, Chuping Peng, Xiumei Zhu, Long Wang, Lu Ye Published: 2026 ABSTRACT AbstractBackgroundNeuropathic pain (NP), a disabling chronic condition with limited treatments, is recapitulated in the chronic constriction injury (CCI) rat model. The role of the miR-1249-3p/VEGFA (vascular endothelial growth factor A) axis in propofol-mediated analgesia remains unclear.MethodsAntagomiR-1249-3p, antagomiR-NC (negative control), a VEGFA-targeting siRNA, and si-NC were delivered intrathecally via lentiviral vectors 3 days before CCI. Propofol (15 mg/kg) was intraperitoneally administered for 7 consecutive days after CCI surgery. Behavioral tests assessed mechanical pain threshold and thermal pain threshold (n = 8). Spinal miR-1249-3p and VEGFA expression were detected by reverse transcription-quantitative polymerase chain reaction. Concentrations of tumor necrosis factor-α, interleukin (IL)-6, IL-1β, and IL-18 in the spinal cord were quantified using ELISA. Protein levels of VEGFA, COX2, iNOS, phospho-NF-κB p65, and total NF-κB p65 were detected using Western blotting. The relationship between miR-1249-3p and VEGFA was validated by dual-luciferase reporter assay.ResultsThe expression of miR-1249-3p decreased and VEGFA increased in the spinal cord of CCI rats (all P < 0.001). The luciferase reporter assay demonstrated that miR-1249-3p targets VEGFA (P < 0.001). Propofol treatment upregulated miR-1249-3p (P < 0.001) and downregulated VEGFA (P < 0.001). The antinociceptive effects and suppression of pro-inflammatory markers of propofol were abolished by antagomiR-1249-3p (P < 0.001), and this abolition was rescued by VEGFA knockdown (P < 0.001). Propofol attenuates NP and neuroinflammation in CCI rats via inhibiting the NF-κB pathway through the miR-1249-3p/VEGFA axis.ConclusionsThese findings suggest that propofol may reduce behavioral signs of NP and suppress associated neuroinflammation in CCI rats by the miR-1249-3p/VEGFA axis.Keywords: Disease Models, Animal; MicroRNAs; Neuralgia; Neuroinflammatory Diseases; NF-kappa B; Propofol; Spinal Cord; Vascular Endothelial Growth Factor A INTRODUCTION Neuropathic pain (NP) is a chronic and severely debilitating condition, affecting approximately 7%–10% of the general population and leading to significant long-term functional impairment [1]. NP arises from a variety of diseases, including systemic conditions such as diabetes and cancer, as well as localized disorders; specific examples of the latter include postherpetic neuralgia, trigeminal neuralgia, and nerve injury resulting from surgical or traumatic procedures [2]. Neuroinflammation, driven by the release of cytokines (e.g., tumor necrosis factor [TNF]-α, interleukin [IL]-1β) and activation of glial cells, is now recognized as a central mechanism underlying the development and maintenance of NP [3,4]. While recent advances in neuromodulation and targeted pharmacotherapy have improved the management of NP, a substantial proportion of patients remain refractory to existing treatments, highlighting the persistent need for novel molecular targets that address the underlying neuroinflammatory drivers of the condition [5]. Propofol (2,6-diisopropylphenol) is a widely used intravenous (IV) agent for the rapid induction of anesthesia and sedation. Apart from the primary anesthetic and sedative effects, the drug holds promise as a therapy because of its ability to decrease cerebral blood flow and metabolism and reduce intracranial pressure [6]. After surgery, propofol reduces the development of hyperalgesia [7]. Propofol also has a protective effect against such sensitization triggers in inflammatory pain states [8]. Prior studies have demonstrated that propofol alleviates NP by inhibiting spinal microglial senescence through the KDM3A/WNT5A axis [9]. Propofol rescues astrocytes from lipopolysaccharide (LPS)-induced inflammatory responses by blocking the NF-κB signaling pathway [10]. Moreover, propofol partially attenuated neuroinflammation caused by complete Freund’s adjuvant by inhibiting the ERK1/2/NF-κB pathway [11]. These observations raise the intriguing possibility that propofol might ameliorate NP by modulating neuroinflammation, yet its specific molecular mechanisms in chronic NP still need to be further explored. In searching for the molecular mediators of propofol’s effects, microRNAs (miRNAs) emerge as compelling candidates. miRNAs are small, endogenous non-coding RNAs that typically bind to complementary sequences within the 3′-untranslated region (3′-UTR) of target messenger RNAs (mRNAs) [12]. This interaction, often involving imperfect base pairing, leads to mRNA degradation or translational repression, thereby fine-tuning gene expression [13]. miRNAs have emerged as critical post-transcriptional regulators, playing increasingly recognized roles in various disease states. Although propofol has been reported to alleviate NP via other miRNA-mediated pathways (e.g., miR-140-3p/JAG1 axis) [14], the diversity of molecular targets for propofol in NP remains to be explored. Notably, miR-1249-3p has been primarily studied in addiction [15], insulin resistance [16], and tumorigenesis [17,18], with only one preliminary small RNA sequencing study suggesting its downregulation in NP rats by spared nerve injury (SNI) [19]. In contrast to well-characterized miRNAs like miR-146a [20] or miR-183 [21] in NP, the role of miR-1249-3p is far less defined. Moreover, it is not clear whether propofol exerts its anti-NP effect by regulating miR-1249-3p. Scientific reports indicate that VEGFA (vascular endothelial growth factor A) is accumulated in both macrophages and neutrophils of bone marrow origin. Partial sciatic nerve ligation models reproducibly show strong upregulation of VEGFA expression in the injured nerve, as demonstrated by increased mRNA and protein levels [22]. Pharmacological inhibition of VEGFA signaling effectively reverses sustained hyperalgesia and motor impairment in discogenic low back pain models [23]. Enhanced translation efficiency of VEGFA mRNA promotes central sensitization and NP after SNI [24]. The regulation of VEGFA by miRNAs (such as miR-185-5p [25] and miR-126 [26]) has been confirmed. miR-1249 has been shown to inhibit the proliferation, migration, invasion, and angiogenesis of colorectal cancer cells through VEGFA [27]. However, whether the miR-1249-3p/VEGFA axis mediates propofol’s antinociceptive effects and suppression of neuroinflammation effects in NP has not been investigated. Based on the above background, the present study aimed to test the hypothesis that propofol alleviates NP and neuroinflammation in chronic constriction injury (CCI)-induced rats by upregulating miR-1249-3p, which directly targets and suppresses VEGFA, thereby inhibiting the NF-κB signaling pathway. MATERIALS AND METHODS 1. Experimental animals and drug preparation Procedures involving experimental animals were performed in strict adherence to the guidelines provided in the Guide for the Care and Use of Laboratory Animals of the National Institute of Health. Male Sprague–Dawley (SD) rats (180–210 g) were obtained from Vital River Co. Ltd. and housed under specific pathogen-free (SPF) conditions. Sample size was determined via power analysis using G*Power 3.1 software, with parameters set as follows: effect size (f) = 0.45, α = 0.05, power (1−β) = 0.85, number of groups = 7, and number of time points = 5. The analysis indicated a minimum required sample size of 3 rats per group; the sample size was therefore set to 8 rats per group to ensure sufficient power and account for potential experimental loss. All rats were allowed to acclimate to the housing facility for at least 7 days under SPF conditions with a controlled 12-hour light/dark cycle, with free access to food and water, before any surgical or experimental procedures were initiated. All animal experiments were approved by the Animal Ethics Committee of Guannan County First People’s Hospital (approval no. 20241023003). All institutional and national guidelines for the care and use of laboratory animals were followed. Appropriate measures were taken to minimize the number and suffering of animals. Propofol (Sigma-Aldrich, catalog numbers D126608) was first dissolved in dimethylsulfoxide (DMSO; 40 mg/mL, Sigma-Aldrich, catalog numbers D2650) and then diluted in pre-warmed normal saline (NS; Henry Schein, catalog number 6985812) to achieve a working concentration of 5 mg/mL. DMSO was used as a solvent at a final concentration of 1.76 mol/L. A dedicated vehicle-control group was established, including sham + vehicle and CCI + vehicle subgroups. Rats in these subgroups received an equivalent volume of the solvent formulation (DMSO diluted in pre-warmed NS, without propofol) and the same dosing schedule as the propofol-treated groups. This vehicle-control group was designed to exclude potential non-specific effects of DMSO (e.g., modulation of membrane permeability or inflammatory pathways) on the experimental outcomes, ensuring that the observed analgesic and anti-inflammatory effects were specifically attributable to propofol. 2. Plasmid construction and grouping The antagomiR-1249-3p, its negative control (antagomiR-NC), a VEGFA-targeting siRNA, and the siRNA’s corresponding negative control (si-NC) were synthesized by Genepharm Co., Ltd. All oligonucleotide sequences were cloned into lentiviral pU6-Luc-Puro vectors (promoter: U6 promoter for driving the expression of antagomiR-1249-3p and si-VEGFA; Luc promoter for auxiliary tracking of transduction efficiency). The viral titer was standardized to 1 × 109 IU/mL. To deliver the lentivirus, a catheter was inserted into the L4–L6 spinal subarachnoid space via a No. 30 needle attached to a Hamilton syringe. Catheter placement was preceded by an injection of 2% lidocaine, which confirmed successful induction of bilateral posterior palsy. A lentiviral suspension was then infused intrathecally. A biological experiment was performed on dissected specimens of the L4–L6 lumbar spinal cord. Three days before CCI surgery, a single injection of 10 μL of lentiviral suspension (total dose: 1 × 107 IU) was slowly administered, followed by a 10 μL saline flush to ensure complete delivery of the lentiviral vector. Rats were divided into the sham group, CCI group (vehicle control), CCI + propofol group, CCI + propofol + antagomiR NC group, CCI + propofol + antagomiR group, CCI + propofol + antagomiR + si-NC group, and CCI + propofol + antagomiR + si-VEGFA group. To confirm the knockdown efficiency of the lentiviral constructs in vivo before the main CCI experiment, a separate pilot cohort of rats was used. Rats (n = 3 per group) received intrathecal injections of either lentivirus expressing antagomiR-1249-3p, antagomiR-NC, si-VEGFA, si-NC, or saline. Total RNA was extracted, and the expression levels of miR-1249-3p or VEGFA mRNA were quantified by quantitative polymerase chain reaction (qPCR). 3. CCI animal model The CCI model of NP was induced in rats according to the established method [28] with stringent standardization procedures to ensure consistency. Briefly, rats were anesthetized, and the sciatic nerve on the left side was exposed via blunt dissection following a femoral-parallel skin incision. All surgeries were performed by a single experienced investigator to minimize operator-dependent variability. The nerve was then ligated loosely with four strands of 4-0 chromic catgut suture, with special attention to standardization: (1) the ligation sites were precisely marked 1 mm proximal to the sciatic trifurcation using a micro-caliper; (2) a calibrated tension meter (or: a standardized weight reference) was applied to ensure consistent ligation tightness, aiming for an approximate 50% reduction in nerve diameter; and (3) a custom-made spacer was used to maintain an exact 1-mm interval between each ligature. After irrigation with physiological saline, the incision was closed. Sham groups underwent the same surgical exposure without ligation. Post-surgery, all animals were maintained in a warm, quiet, and standard housing facility. Following a 12-hour recovery period after CCI induction, rats underwent a 7-day course of intraperitoneal (IP) propofol at a dosage of 15 mg/kg. Concurrently, sham and CCI rats received caudal vein injections of parallel volumes of NS. The rationale for using different routes was primarily practical, as chronic IV catheterization in rats for multi-day studies presents significant technical and welfare challenges, whereas IP injection is a robust and standard method for repeated systemic dosing in rodent models. The authors acknowledge that this introduces a potential confounding variable (route of administration), which they have directly addressed in a supplemental experiment. Rats were randomly assigned to experimental groups using a random number table. Each group consisted of 8 rats unless otherwise specified. All behavioral tests and biochemical analyses were performed by investigators blinded to group allocation to minimize bias. 4. Tissue homogenization After euthanasia, the L4–L6 segments of the lumbar spinal cord were rapidly dissected, snap-frozen in liquid nitrogen, and stored at –80°C. For protein or RNA extraction, tissues were homogenized on ice using a Polytron tissue disruptor in 1 mL of RIPA lysis buffer (for protein) or TRIzol reagent (Takara, catalog numbers 9109) (for RNA) per 50 mg of tissue. The homogenate was then centrifuged at 12,000 × g for 15 minutes at 4°C, and the supernatant was collected for subsequent analysis. 5. RNA isolation and RT-qPCR Total RNA extraction from spinal cord tissues was conducted with a TRIzol kit (Takara, catalog numbers 9109). Following extraction, RNA concentration was quantified on a NanoDrop spectrophotometer (ND-1000; NanoDrop Technologies). Subsequently, cDNA was synthesized from the purified RNA using a PrimeScript RT reagent kit (Takara, catalogue number RR047B). Reverse transcription-qPCR (RT-qPCR) was then carried out with a SYBR Premix Ex TaqTM II kit (Takara, catalogue number RR820A) on a StepOne Real-Time PCR System (Applied Biosystems). GAPDH and U6 served as internal controls for normalizing lncRNA, mRNA, and miRNA expression, respectively, and the 2−ΔΔCt method was applied for relative quantification. The primer sequences are shown in Supplementary Table 1. 6. Pain threshold assessment Behavioral testing for mechanical and thermal sensitivity was performed on post-CCI days 0, 3, 7, 14, and 21. The paw withdrawal mechanical threshold (PWMT) test was conducted by placing the rats on a metal mesh floor and allowed an adaptation period of 25 minutes. Thereafter, the plantar surface was stimulated with a von Frey filament (Bioseb) through incrementally applied forces. A positive response was noted when the animal withdrew the hind paw. Each application lasted approximately 5 seconds, with a 15-second interval between applications. The paw withdrawal thermal latency (PWTL) test was conducted similarly in that the rats were placed on a plate. A heat-stimulating device (Bioseb) was applied under the plate and directed at the plantar surface to produce a reaction; in this case, the latency to withdrawal was recorded using a maximum stimulus duration of 18 seconds to prevent damage. All behavioral tests were conducted by experimenters who were blinded to the group assignments of the rats throughout the testing and data recording process. To minimize the potential confounding influence of acute sedation on pain-related behavioral assessments, all PWMT and PWTL tests were performed at least 18–24 hours after the last dose of propofol (or vehicle) on the previous day. This interval was chosen based on the known short elimination half-life of propofol in rats, ensuring that animals were fully alert and ambulatory during testing, and that the observed effects reflected sustained analgesic modulation rather than acute sedation. During handling and the entire behavioral testing process, all animals exhibited normal spontaneous locomotion (e.g., active exploration of the testing environment, unobstructed movement across the metal mesh floor or test plate), no overt ataxia (e.g., no stumbling, swaying, or inability to maintain balance), and intact righting reflex (immediate recovery to upright posture when gently placed in a supine position). These observations confirm that propofol had no residual sedative effects at the time of testing, and the changes in pain thresholds were not attributable to impaired motor function or altered arousal state. 7. ELISA assay Spinal cord tissue concentrations of four inflammatory factors, including IL-6 (R&D systems, catalogue number M6000B, Lot P342576), TNF-α (R&D systems, catalogue number MTA00B, Lot MTA00B), IL-1β (R&D systems, catalogue number DY401, Lot NP2715111), and IL-18 (R&D systems, catalogue number NBP3-06799) were determined by using specific commercially available ELISA kits. Briefly, tissue homogenates were centrifuged at 12,000 × g for 15 minutes at 4°C, and the supernatants were collected. Samples and standards were added to pre-coated wells and incubated for 2 hours at room temperature. After washing four times with wash buffer, detection antibodies were added and incubated for 1 hour, followed by streptavidin-HRP (horseradish peroxidase) incubation for 30 minutes. 3,3′,5,5′-Tetramethylbenzidine substrate was added, and the reaction was stopped with 2 N H2SO4 after 20 minutes. Absorbance was measured at 450 nm using a microplate reader (BioTek). All samples were assayed with three biological replicates and three technical replicates, and cytokine concentrations were calculated based on standard curves generated for each assay. 8. Western blotting Total protein extraction was performed with RIPA reagent (Thermo Fisher Scientific, catalogue number 89900), and concentrations were quantified with a BCA Protein Assay Kit (KeyGEN Biotech, catalogue number 23227). The protein samples were then separated by 10% SDS-PAGE at 100 V, followed by electrophoretic transfer onto a PVDF membrane (Millipore Corporation). After blocking, the membrane was probed with a primary antibody overnight at 4°C. The primary antibodies include VEGFA (Abcam, catalog number: ab52917, Clone number: EP1176Y, 1:1000, Rabbit), COX2 (Abcam, catalog number: ab179800, Clone number: EPR12012, 1:1000, Rabbit), iNOS (Abcam, catalog number: ab178945, Clone number: EPR16635, 1:1000, Rabbit), p-NF-κB (Abcam, catalog number: ab76302, Clone number: EP2294Y, 1:1000, Rabbit), NF-κB (Abcam, catalog number: ab32536, Clone number: E379, 1:1000, Rabbit), and GAPDH (Abcam, catalog number: ab181602, Clone number: EPR16891, 1:1000, Rabbit). The following day, it was washed thrice with TBST (Tris-buffered saline with Tween-20) and incubated with the secondary antibody of goat anti-rabbit IgG (Abcam, catalog number: ab6721, 1:5000) conjugated with HRP for 1 hour. Protein bands were ultimately visualized using a chemiluminescence detection kit (Thermo Fisher Scientific, catalogue number 32209). Each experiment was performed with 3 independent biological replicates and 3 technical replicates. 9. Cell culture and dual-luciferase reporter assay The culture of HEK‐293T cells (ATCC) was conducted in complete DMEM (catalogue number 11995065, Gibco), enriched with 10% fetal bovine serum (Invitrogen, catalogue number 26140) at 37°C in a 5% CO2 incubator. For the luciferase reporter assay, the interaction between miR-1249-3p and the VEGFA 3′-UTR was assessed using a dual-luciferase reporter assay. Briefly, the pmirGLO vector harboring either WT or MUT VEGFA 3′-UTR sequences was constructed. Transfection was performed when HEK‐293T cells reached 60%–70% confluence in 24-well plates. The transfection system (200 μL per well) was prepared as follows: 0.8 μg of WT/MUT pmirGLO reporter vector, 50 nM of miR-1249-3p mimic, mimic NC, miR-1249-3p inhibitor, or inhibitor NC were mixed with 1 μL of Lipofectamine 3000 reagent (Invitrogen). Before conducting the luciferase activity assay, the transfection efficiency of miR-1249-3p mimic and inhibitor was verified by RT-qPCR (Supplementary Fig. 1). After a 48-hour incubation, the luciferase activity was quantified using the Dual-Luciferase Reporter Assay System (Promega) on a GloMax 20/20 Luminometer (Promega) according to the manufacturer’s instructions. Firefly luciferase activity was normalized to Renilla luciferase activity to correct for transfection efficiency variations. All experiments were performed in 3 technical replicates. All reagents and materials used in this study were summarized in Supplementary Table 2. 10. Comparison of IP versus IV administration Although IV is a clinical route of administration, in long-term multi-dose rat experiments, IP injections are technically more feasible and cause less stress to the animals. In the initial design of this study, to facilitate operation, the control group was given solvent via tail vein injection. Due to the difference in injection routes, confounding variables might have been introduced. Therefore, a supplementary experiment was designed to verify the consistency of the effects of the administration routes. The experimental results observed that the administration route itself was not a confounding factor influencing the outcome variables of this study. The observed differences in effects were clearly attributed to the pharmacological action of propofol. These rats were randomly assigned to four groups (n = 4 per group) and received daily injections for 7 days, starting 12 hours post-surgery, as follows: 1) CCI + vehicle (IV); 2) CCI + vehicle (IP); 3) CCI + propofol (15 mg/kg, IV); and 4) CCI + propofol (15 mg/kg, IP). Vehicle and propofol solutions were prepared as described above. On days 0, 3, 7, 14, and 21 post-CCI, a subset of animals from each group was euthanized, and spinal cord tissues were collected. The levels of a key pro-inflammatory cytokine, IL-6, TNF-α, IL-1β, and IL-18 were quantified in tissue homogenates using a commercial ELISA kit (the method is the same as mentioned above). 11. Statistical analysis All behavioral experiments were performed with eight biological replicates per group (n = 8), another experiment was conducted on three rats with three repetitions. Data are presented as mean ± standard deviation. All calculations were performed on GraphPad Prism 9.0 (GraphPad). For comparisons of continuous variables (e.g., PWMT, PWTL, cytokine levels, protein expression) across multiple groups (7 groups) and multiple points (0, 3, 7, 14, 21 days), two-way repeated-measures ANOVA was used. Student’s t-test was applied for pairwise comparisons between two groups. For post-hoc pairwise comparisons, Tukey’s multiple comparison test was used for overall pairwise comparisons among all 7 groups. The Bonferroni correction was applied for targeted pairwise comparisons between key mechanistic groups to strictly control the family-wise error rate. A P value < 0.05 was considered statistically significant. RESULTS 1. Propofol attenuates pain hypersensitivity and spinal inflammation in CCI rats This study investigated the possible neuroprotective effects of propofol in a rat model of NP (n = 8 per group). Behavioral tests (PWMT for mechanical pain threshold and PWTL for thermal pain threshold) were performed on post-CCI days 0 (baseline), 3, 7, 14, and 21. At baseline (day 0), there were no significant differences in PWMT or PWTL between the sham group and the CCI group (all P > 0.05). After CCI induction, the mechanical and thermal pain thresholds of rats in the CCI group were significantly reduced compared with the sham group at days 3, 7, 14, and 21 (PWMT: P < 0.001, F[8,105] = 18.9, Partial η2 = 0.59; PWTL: P < 0.001, F[8,105] = 15.3, Partial η2 = 0.31; Fig. 1A, B). Compared with the sham group, PWMT decreased by 46% (day 3), 66% (day 7), 67% (day 14), and 69% (day 21) (all P < 0.001), and PWTL decreased by 26% (day 3), 50% (day 7), 49% (day 14), and 60% (day 21) (all P < 0.001). In contrast, IP injection of propofol significantly increased the reduced PWMT and PWTL in CCI rats: compared with the CCI group, PWMT was increased by 26% (day 3), 50% (day 7), 46% (day 14), and 49% (day 21) (all P < 0.001), and PWTL was increased by 20% (day 3), 35% (day 7), 30% (day 14), and 47% (day 21) (all P < 0.001). Pro alleviates NP and spinal cord inflammation in CCI rats. (A) Time course of mechanical allodynia, assessed by the PWMT using von Frey filaments at days 0, 3, 7, 14, and 21 post-CCI (n = 8). Data were analyzed by two-way ANOVA with Tukey’s post hoc test. ***P < 0.001 vs. sham+vehicle group or CCI + vehicle group. (B) Thermal hyperalgesia, assessed by the PWTL using the Hargreaves test at days 0, 3, 7, 14, and 21 post-CCI (n = 8). Data were analyzed by two-way ANOVA with Tukey’s post hoc test. ***P < 0.001 vs. sham + vehicle group or CCI + vehicle group. (C–F) Spinal cord levels of pro-inflammatory cytokines (C) TNF-α, (D) IL-6, (E) IL-1β, and (F) IL-18 quantified by ELISA (n = 3 independent experiments performed in triplicate). Data are presented as mean ± standard deviation. Data were analyzed by two-way ANOVA with Tukey’s post hoc test. ***P < 0.001 vs. sham + vehicle group or CCI + vehicle group. PWMT: paw withdrawal mechanical threshold, CCI: chronic constriction injury, PWTL: paw withdrawal thermal latency, Pro: propofol, TNF: tumor necrosis factor, IL: interleukin, NP: neuropathic pain. ELISA was used to assess the levels of neuroinflammation-associated cytokines. CCI markedly increased the levels of TNF-α (P < 0.001, F[2,21] = 551.0, Partial η2 = 0.98; Fig. 1C), IL-6 (P < 0.001, F[2,21] = 350.1, Partial η2 = 0.97; Fig. 1D), IL-1β (P < 0.001, F[2,21] = 265.3, Partial η2 = 0.96; Fig. 1E), and IL-18 (P < 0.001, F[2,21] = 664.0, Partial η2 = 0.98; Fig. 1F) by 3.0, 5.4, 2.1, 8.5 folds, respectively, while propofol significantly reduced these cytokine levels (all P < 0.001 vs. CCI group) (all P < 0.001; Fig. 1C–F). 2. The expression of miR-1249-3p and VEGFA in the CCI model and their relationship Compared to the sham group, CCI rats had significantly lower levels of miR-1249-3p at all time points tested, including days 3, 7, 14, and 21 after CCI surgery, with a reduction of 0.21-, 0.25-, 0.49-, and 0.65-fold, respectively, and the expression level was the lowest on the 21st day (P < 0.001, F[4,70] = 30.4, Partial η2 = 0.63; Fig. 2A). After CCI surgery, VEGFA expression was found to be upregulated at all time points in the spinal cord tissue of the rat model, with an increase of 1.1, 1.5, 1.8, and 2.0 fold, respectively, on the 3, 7, 14, and 21 days, and the expression level was the highest on the 21st day (P < 0.001, F[4,70] = 41.0, Partial η2 = 0.70; Fig. 2B). To address the potential interaction between miR-1249-3p and VEGFA, the binding site and mutation sequence were predicted using the starBase database (Fig. 2C). A dual-luciferase reporter assay verified the direct interaction. It demonstrated that the miR-1249-3p mimic diminished the luciferase activity of the WT-VEGFA reporter by approximately 45% compared to control (P < 0.001), while the miR-1249-3p inhibitor enhanced it by approximately 60% (P < 0.001). On the other hand, neither the mimic nor the inhibitor altered the activity of the MUT-VEGFA (F[4,20] = 13.1, Partial η2 = 0.72; Fig. 2D). Expression dynamics of miR-1249-3p and VEGFA and their interaction in CCI rats. (A, B) Expression levels of miR-1249-3p (A) and VEGFA mRNA (B) in spinal cord tissues of sham and CCI rats at the indicated time points post-surgery, analyzed by RT-qPCR (n = 3 independent experiments performed in triplicate). Data were analyzed by two-way ANOVA followed by Tukey’s post hoc test. ***P < 0.001 vs. sham group at the corresponding time point, ns: not significant. (C) Predicted binding site of miR-1249-3p within the VEGFA 3′-UTR. (D) Validation of direct targeting via dual-luciferase reporter assay in HEK293T cells (n = 3 independent experiments performed in triplicate). Data are presented as mean ± standard deviation. Data were analyzed by two-way ANOVA followed by Tukey’s post hoc test. ***P < 0.001 vs. control group. CCI: chronic constriction injury, mRNA: messenger RNA, NC: negative control, RT-qPCR: reverse transcription-quantitative polymerase chain reaction, 3′-UTR: 3′-untranslated region. 3. The effects of miR-1249-3p and VEGFA on the pain threshold of CCI rats treated with propofol Before inducing CCI, the efficacy of the lentiviral constructs were validated in a pilot study (n = 3). Both antagomiR-1249-3p and si-VEGFA achieved significant knockdown in the spinal cord 7 days after intrathecal delivery (P < 0.001; Supplementary Fig. 2). Compared to the CCI group, propofol significantly increased the expression of miR-1249-3p by 1.7 fold (P < 0.001), an effect reversed by the injection of a subsequent antagomiR, the expression level of miR-1249-3p decreased to be similar to that of the CCI group (P < 0.001, F[3,28] = 37.6, Partial η2 = 0.80, n = 3; Fig. 3A). Propofol significantly inhibited VEGFA mRNA expression (P < 0.001). Notably, the inhibitory effects of propofol on VEGFA were restored when miR-1249-3p was downregulated (P < 0.001). In contrast, si-VEGFA treatment significantly reduced the specific abundance of VEGFA (P < 0.01, F[5,42] = 39.8, Partial η2=0.83, n = 3; Fig. 3B). In addition, the inhibition of miR-1249-3p caused a further reduction in the mechanical and thermal pain thresholds in propofol-treated CCI rats on the 3, 7, 14, and 21 days. Compared with the CCI + propofol + antagomiR NC group, PWMT decreased by 88% (day 3), 94% (day 7), 93% (day 14), and 95% (day 21) (all P < 0.001), and PWTL decreased by 95% (day 3), 91% (day 7), 89% (day 14), and 94% (day 21) (all P < 0.001) in the CCI + propofol + antagomiR-1249-3p group. Knocked-down VEGFA partially abrogated the enhancing effect of miR-1249-3p inhibition on the pain sensitivity of the rats, PWMT increased by 23% (day 3), 69% (day 7), 28% (day 14), and 47% (day 21) (all P < 0.01), and PWTL increased by 23% (day 3), 42% (day 7), 64% (day 14), and 34% (day 21) (all P < 0.01) in the CCI + propofol + antagomiR-1249-3p group (F[16,175] = 4.8, Partial η2=0.30, Fig. 3C; F[16,175] = 13.2, Partial η2 = 0.55, n = 8, Fig. 3D). Role of miR-1249-3p and VEGFA in modulating pain thresholds in Pro-treated CCI rats. (A) miR-1249-3p expression in the spinal cord following antagomiR-1249-3p administration, analyzed by RT-qPCR (n = 3 independent experiments performed in triplicate). Data were analyzed by one-way ANOVA followed by Bonferroni's post hoc test. ***P < 0.001 vs. CCI + vehicle group or CCI + Pro + antagomiR NC group. (B) VEGFA mRNA levels in the spinal cord under miR-1249-3p inhibition and VEGFA knockdown (n = 3 independent experiments performed in triplicate). Data are presented as mean ± standard deviation. Data were analyzed by one-way ANOVA followed by Bonferroni's post hoc test. ***P < 0.001 vs. CCI + vehicle or CCI + Pro + antagomiR NC group, **P < 0.01 vs. CCI + Pro + antagomiR + si-NC group. (C, D) Time course of mechanical allodynia, assessed by the (C) PWMT using von Frey filaments, and thermal hyperalgesia, assessed by the (D) PWTL using the Hargreaves test in CCI + Pro, CCI + Pro + antagomiR NC, CCI + Pro + antagomiR, CCI + Pro + antagomiR + si-NC, and CCI + Pro + antagomiR + si-VEGFA groups (n = 8). Data were analyzed by two-way repeated-measures ANOVA followed by Tukey’s post hoc test. ***P < 0.001 vs. CCI + Pro, **P < 0.01 vs. CCI + Pro + antagomiR-1249-3p + si-NC group. CCI: chronic constriction injury, Pro: propofol, NC: negative control, mRNA: messenger RNA, PWMT: paw withdrawal mechanical threshold, PWTL: paw withdrawal thermal latency, RT-qPCR: reverse transcription-quantitative polymerase chain reaction. 4. Inhibition of miR-1249-3p reversed the protective effect of propofol on CCI rats by targeting VEGFA The effect of miR-1249-3p and VEGFA on the inflammatory response was studied in the CCI rat model. The spinal cord tissue was analyzed by ELISA kits for pro-inflammatory cytokines. Inhibition of miR-1249-3p significantly elevated the levels of multiple pro-inflammatory cytokines compared to the CCI + Pro group: TNF-α (1.6-fold, F[4,30] = 81.0, Partial η2 = 0.92; P < 0.001), IL-6 (3.1-fold, F[4,30] = 173.9, Partial η2 = 0.96; P < 0.001), IL-1β (2.2-fold, F[4,30] = 735.0, Partial η2 = 0.99; P < 0.001), and IL-18 (2.8-fold, F[4,30] = 245.1, Partial η2 = 0.97; P < 0.001) (Fig. 4). To elucidate the associated signaling pathways, the authors examined the protein expression of COX2, iNOS, and the NF-κB pathway proteins by Western blot. The inhibition of miR-1249-3p increased the level of expression of VEGFA (2.4-fold, F[4,10] = 72.4, Partial η2 = 0.96; P < 0.001) (Fig. 5A), COX2 (2.1-fold, F[4,10] = 54.7, Partial η2 = 0.96; P < 0.001) (Fig. 5B), iNOS (2.6-fold, F[4,10] = 179.2, Partial η2 = 0.99; P < 0.001) (Fig. 5C), and p-NF-κB/NF-κB ratio (2.0-fold, F[4,10] = 26.3, Partial η2 = 0.91; P < 0.001) (Fig. 5D). These effects were reversed by co-knockdown of VEGFA, which decreased these protein levels, the levels of VEGFA, COX2, iNOS, and the ratio of p-NF-κB/NF-κB decreased by 0.47, 0.33, 0.38, and 0.34 times, respectively (Fig. 5). miR-1249-3p inhibition elevates pro-inflammatory cytokines via VEGFA. Spinal cord concentrations of (A) TNF-α, (B) IL-6, (C) IL-1β, and (D) IL-18 measured by ELISA following modulation of miR-1249-3p and VEGFA (n = 3 independent experiments performed in triplicate). Data are presented as mean ± standard deviation. Data were analyzed by one-way ANOVA followed by Bonferroni's post hoc test. ***P < 0.001 vs. CCI + Pro or CCI + Pro + antagomiR group. TNF: tumor necrosis factor, CCI: chronic constriction injury, Pro: propofol, NC: negative control, IL: interleukin. The miR-1249-3p/VEGFA axis regulates the NF-κB signaling pathway in the spinal cord of CCI rats. Representative western blots and quantification of (A) VEGFA, (B) COX2, (C) iNOS, and (D) p-NF-κB in spinal cord tissues (n = 3 independent experiments performed in triplicate). Data are presented as mean ± standard deviation. Data were analyzed by one-way ANOVA followed by Bonferroni’s post hoc test. ***P < 0.001 vs. CCI + Pro or CCI + Pro + antagomiR group. **P < 0.01 vs. CCI + Pro + antagomiR group. CCI: chronic constriction injury, Pro: propofol, NC: negative control. 5. Administration route does not affect outcome measures To ensure that the observed effects were attributable to propofol itself rather than the route of administration, outcomes were compared between IP and IV delivery. As shown in Supplementary Fig. 3, whether administered IP or IV, propofol significantly restored the impaired pain threshold (Supplementary Fig. 3A, B). Whether given by IP or IV, propofol significantly reduced the levels of inflammatory factors in rats (Supplementary Fig. 3–FC). There was no significant difference between the different administration methods. This result indicates that, in the context of the authors’ model and treatment protocol, the pharmacological effects and baseline state of propofol are comparable between IP and IV administration. DISCUSSION NP is a complicated and challenging clinical condition that is difficult to manage because of its chronic nature and poor responsiveness to many treatments. Peripheral and central sensitization, combined with complex neuroimmune interactions, underlie the rationale behind the failure of conventional analgesic treatments to relieve symptoms, thus making clinical management quite problematic [29]. While propofol has been shown to reduce postoperative pain and pain-associated anxiety in acute/chronic pain models, its role and underlying mechanisms in chronic NP remain understudied. The present study fills this gap by demonstrating that propofol attenuates pain hypersensitivity and neuroinflammation in CCI-induced NP rats, which are mediated by a novel miR-1249-3p/VEGFA/NF-κB axis. Earlier investigations have shown that propofol anesthesia is associated with less postoperative pain compared to sevoflurane [30]. Propofol was found to decrease pain-associated anxiety-like behaviors in both acute and chronic pain models [31]. Beyond its established anesthetic properties, the authors’ findings position propofol as a modulator of NP. The restoration of pain thresholds in CCI rats suggests that propofol's suppression of pain hypersensitivity extends beyond acute pain management, potentially addressing the neuroimmune dysregulation characteristic of chronic NP. This expands the therapeutic repertoire for NP. This investigation revealed a downregulation of miR-1249-3p in the spinal cord of CCI rats, which aligns with the well-documented dysregulation of miRNAs in NP, though importantly, such dysregulation is not uniform across miRNA families. miR-122-5p is downregulated in CCI-induced NP and exerts analgesic effects by targeting PDK4 to suppress neuronal sensitization [32]. miR-140 is also downregulated in CCI rats and ameliorates NP via inhibiting S1PR1-mediated neuroinflammation [33]. miR-101 is upregulated in CCI models and alleviates NP by targeting MKP-1 to aggravate NP [34]. The present study was the first to identify miR-1249-3p as a regulator of NP through the VEGFA/NF-κB axis. Unlike miR-122-5p (targeting PDK4), miR-140 (targeting S1PR1), or miR-101 (targeting MKP-1), miR-1249-3p uniquely links propofol-mediated analgesia to neuroinflammatory modulation via direct targeting of VEGFA, a key angiogenic and inflammatory mediator. This distinct mechanism underscores the novel contribution of these findings. To further delineate the downstream effector of miR-1249-3p, VEGFA was investigated as a potential target. Indeed, the direct binding between miR-1249-3p and VEGFA’s 3′-UTR was validated by dual-luciferase reporter assay, and functional experiments confirmed that miR-1249-3p inhibition upregulates VEGFA, while VEGFA silencing reverses the pro-nociceptive and pro-inflammatory effects of miR-1249-3p inhibition. This study’s findings in the spinal cord align with, yet extend, previous observations in other pain-relevant tissues. For instance, in dorsal root ganglia, peripheral nerve injury downregulates miR-126, leading to VEGFA upregulation [26]. Similarly, in lumbar disc tissues, the miR-185-5p/VEGFA axis modulates pain from disc herniation [25]. While these studies highlight the importance of miRNA-mediated VEGFA regulation across different anatomical sites, the authors’ work is the first to demonstrate this regulatory axis specifically in the spinal cord following CCI and its modulation by propofol, further expanding the functional spectrum of miR-1249-3p. These findings complement existing literature by identifying a novel miR-1249-3p/VEGFA axis underlying propofol’s antinociceptive effects in NP. Previous studies have reported that propofol alleviates NP through miR-140-3p/JAG1 [14]. This highlights the multi-targeted nature of propofol in NP and expands the repertoire of miRNA-mediated mechanisms for this drug. Given that VEGFA is known to activate pro-inflammatory signaling cascades such as NF-κB, the authors next examined whether this pathway underlies the observed neuroinflammatory changes. The hallmark features of NP include spinal cord glial cell activation and cytokine production. Several cytokines, including IL-6, TNF-α, IL-1β, and IL-18, have well-established roles in amplifying nociceptive signaling in rodents, as demonstrated by both behavioral and neurophysiological evidence [35,36]. It is worth noting that different miRNAs can converge on similar inflammatory pathways. For instance, miR-124-3p (distinct from the miR-1249-3p investigated here) was shown to reduce NP in a CCI model by downregulating IL-6, IL-1β, and TNF-α [37]. In parallel, inhibition of miR-1249-3p attenuated propofol’s anti-inflammatory effects, elevating both cytokine levels and key inflammatory enzymes COX2 and iNOS. These inflammatory mediators are not independent but are coordinately regulated by shared upstream signaling pathways. Notably, the upregulation of COX2 and iNOS coincided with NF-κB pathway activation (increased p-NF-κB/NF-κB ratio), positioning NF-κB as a likely mediator. This aligns with established inflammatory paradigms: just as LPS stimulates COX2/iNOS via NF-κB in immune cells [38], peripheral nerve injury in CCI similarly triggers heightened expression of COX2 and iNOS [39], likely through NF-κB-dependent mechanisms. The results of the present study show that miR-1249-3p inhibition increases the p-NF-κB/NF-κB protein ratio; knockdown of VEGFA not only reduced VEGFA levels but also significantly attenuated the increase in the p-NF-κB/NF-κB ratio, indicating that the miR-1249-3p/VEGFA axis modulates NF-κB activation. Combined with the downregulation of COX2, iNOS, and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-18) by propofol, the authors propose a complete mechanism: propofol upregulates miR-1249-3p, which directly targets and suppresses VEGFA, thereby inhibiting the NF-κB signaling pathway, reducing neuroinflammation, and alleviating NP in CCI rats. Accumulating evidence demonstrates that sex is a fundamental biological determinant of pain processing: in males, higher circulating testosterone levels are associated with elevated pain thresholds, whereas in females, cyclical fluctuations in estradiol, particularly during low-estrogen phases, potentiate pain sensitivity, intensity, and affective perception [40]. Consistent with this, epidemiological and preclinical studies consistently report greater pain sensitivity and higher prevalence of clinical pain conditions in females compared to males [41]. Notably, approximately 50% of chronic pain disorders exhibit female-predominant incidence, while only about 20% show male predominance [42]. Although the authors have clarified the mechanism by which propofol exerts its effects in male rats through the miR-1249-3p/VEGFA/NF-κB pathway, it remains to be determined whether these findings apply to females. A critical consideration in interpreting the authors’ findings is whether the observed reversal of pain hypersensitivity by propofol represents true analgesia or is secondary to its well-known sedative properties. Several lines of evidence argue against sedation as the primary confounder in this study. First, the dosing regimen (15 mg/kg/day, IP for 7 days) and the timing of behavioral assessments (conducted 18–24 hours post-injection) were designed to capture sustained neuroadaptations rather than acute drug effects. The short plasma half-life of propofol in rodents ensures that significant sedative effects would have dissipated well before testing. Second, the restoration of pain thresholds by propofol was specific and mechanistically reversible: it was abolished by inhibition of miR-1249-3p and subsequently rescued by knockdown of its target VEGFA. A non-specific sedative effect would be unlikely to show such precise molecular dependence. Third, propofol treatment did not produce obvious ataxia or loss of righting reflex at the dose used. Therefore, while some contribution of an altered arousal state cannot be completely ruled out, the molecular specificity and sustained nature of the effects strongly support the conclusion that propofol attenuates NP-like behaviors via the identified miR-1249-3p/VEGFA/NF-κB axis. That propofol alleviates established NP through a defined molecular axis invites consideration of its potential repurposing beyond anesthesia. A compelling analogy can be drawn to ketamine, an anesthetic agent whose low, subanesthetic doses have revolutionized the treatment of refractory depression and chronic pain conditions by modulating glutamatergic signaling and neuroinflammation [43,44]. Similarly, propofol, acting via the miR-1249-3p/VEGFA/NF-κB pathway, may offer a novel mechanistic approach to NP management. The critical next question is whether these beneficial effects can be achieved at doses that minimize sedation and cognitive impairment, thereby enabling feasible long-term or intermittent outpatient use. This conceptual shift, from viewing propofol solely as a general anesthetic to investigating it as a targeted neuromodulator, is supported by the authors’ mechanistic data and opens a new direction for translational research in chronic pain. Several critical translational questions must be addressed to bridge these preclinical findings to potential human therapies. In this study, propofol was administered intraperitoneally, a standard route for systemic drug delivery in rodent models but not directly applicable to humans. The clinically established route for propofol is IV infusion. The authors’ supplementary data (Supplementary Fig. 3) demonstrate that the antinociceptive and anti-neuroinflammatory effects are comparable between IP and IV routes in rats at the tested dose, supporting the pharmacological relevance of their findings. For chronic pain management, potential clinical strategies could include short-term IV infusions in controlled settings (analogous to ketamine infusion therapy) or the development of alternative delivery systems (e.g., slow-release formulations, intranasal delivery, or targeted nanocarriers) to enable sustained drug levels with an improved convenience and safety profile. A paramount concern for repurposing an anesthetic agent is whether its therapeutic effect can be dissociated from sedation. The behavioral assessments were deliberately conducted 18–24 hours post-injection, well beyond propofol’s short elimination half-life, to capture sustained analgesic modulation rather than acute sedation. Nonetheless, determining the existence of a “therapeutic window” where analgesia occurs without significant hypnotic effects is essential. Future studies must systematically titrate doses to identify subanesthetic or non-sedating regimens that retain efficacy, a paradigm successfully employed for ketamine in pain and depression. The persistence of therapeutic effects is a key factor in determining its clinical practicality. If the effect is short-lived, propofol may only be suitable for emergency treatment of acute pain episodes. If the effect is long-lasting, it may indicate that it has the potential to modify the disease by regulating the neuroimmune cascade, thereby supporting its use in long-term treatment cycles. Future preclinical studies must include a longer observation period after a limited treatment course to characterize the persistence of antinociceptive and anti-neuroinflammatory effects, which will directly provide a basis for decisions regarding treatment frequency and duration in clinical trial design. In summary, the identification of the miR-1249-3p/VEGFA/NF-κB axis provides a mechanistic basis for exploring the application of propofol in NP. However, its successful translation will depend on the simultaneous efforts of dose optimization (to distinguish analgesia from sedation), development of administration regimens (to enable feasible long-term use), and pharmacokinetic formulations (to achieve optimal administration). Addressing these challenges in subsequent studies is crucial for evaluating whether propofol can move from the operating room to the pain clinic. Several limitations of the present study should be acknowledged, which also highlight directions for future research. First, regarding experimental design and controls, this study did include a dedicated vehicle-control group (sham + vehicle and CCI + vehicle) receiving the solvent formulation (DMSO + NS) without propofol, aiming to exclude non-specific effects of the vehicle. However, DMSO itself may have potential biological activities (e.g., modulating membrane permeability or inflammatory pathways), which could introduce subtle interference to the experimental outcomes. Therefore, future studies should employ clinically relevant propofol carriers (e.g., lipid emulsions) as the solvent to further eliminate such potential confounding factors and confirm the pharmacological specificity of propofol. Second, the use of lentiviral vectors for gene modulation, while effective (as confirmed by pre-CCI qPCR data in Supplementary Fig. 2), may introduce non-specific immune responses or off-target effects. Although the authors included a NC, future investigations should consider alternative delivery methods, such as chemically modified oligonucleotides or nanoparticle-based systems, to more precisely isolate gene-silencing effects and enhance translational safety. Third, the absence of in vitro experiments limits the authors’ mechanistic insight into cell-type-specific contributions. The functional role of the miR-1249-3p/VEGFA axis in neuroinflammation could be further validated through direct interventions in primary microglial, astrocytic, or neuronal cultures. Such approaches would help delineate whether propofol’s effects are mediated primarily through glial modulation, neuronal signaling, or both. Fourth, while propofol was administered intraperitoneally in this study—diverging from its clinical IV route—the authors’ comparative experiment (Supplementary Fig. 3A–E) confirmed equivalent effects on spinal inflammatory markers between IP and IV administration in this model. Nevertheless, pharmacokinetic differences may still influence drug bioavailability and duration of action. Future work should include pharmacokinetic profiling and explore sustained-release formulations to address propofol’s short half-life, which poses a practical barrier to its chronic use in NP. Fifth, the authors’ behavioral assessments relied on reflex-based tests (PWMT and PWTL), which capture evoked hypersensitivity, but not spontaneous or affective dimensions of chronic pain. Incorporating complementary measures such as conditioned place preference/aversion, spontaneous pain behaviors (e.g., limb guarding), or motivational assays (e.g., burrowing, nest-building) would provide a more comprehensive understanding of propofol’s impact on the multifaceted experience of NP. Sixth, the present study was conducted exclusively in male SD rats and did not investigate potential sex-related differences in the mechanisms of NP, neuroinflammatory responses, or the pharmacological effects of propofol. Future studies should include both male and female rats to clarify whether the miR-1249-3p/VEGFA/NF-κB axis mediates propofol’s effects in a sex-dependent manner, which will enhance the translational relevance of the findings to clinical populations. Seventh, the authors’ experimental timeline ended with the last propofol administration. Consequently, the authors could not determine the durability of the observed effects. It remains unknown whether the amelioration of pain and neuroinflammation persists after drug withdrawal, which would imply a potential disease-modifying action, or rapidly subsides, indicating a purely suppressive effect. Longitudinal studies with extended post-treatment observation periods (e.g., 7–14 days after the last dose) are essential to address this pivotal pharmacodynamic property. While the behavioral tests were conducted 18 to 24 hours after administration, quantitative assessments of locomotor activity (e.g., open field test) were not performed at the time of pain testing. Future studies incorporating such direct measures of motor function would provide even stronger evidence to dissociate pure pain-relieving effects from any potential subtler alterations in mobility. Finally, although the rescue experiments demonstrate the functional relevance of the miR-1249-3p/VEGFA axis using single effective doses, they do not establish a full dose-response relationship for propofol or genetic modulators. Future studies employing graded doses of antagomiR-1249-3p and si-VEGFA would help quantify the contribution of this pathway relative to other potential mechanisms of propofol’s action and inform therapeutic dosing strategies. Closely related to this is the issue of sub-anesthetic doses. In clinical practice, the use of propofol for chronic pain management requires the formulation of a plan that can provide continuous analgesia without causing deep sedation. In the present study, the limitation of a single dose failed to achieve this plan. Therefore, such “sub-anesthetic” regimens (for example, continuous low-dose infusion or repeated low-dose bolus injections) are the key next step in evaluating the translational potential of propofol outside the operating room. In summary, while this study identifies a novel mechanism through which propofol alleviates NP, these limitations underscore the need for further mechanistic, pharmacokinetic, and behavioral investigations to advance toward clinical translation. In conclusion, the authors’ research findings reveal that propofol reduces pain hypersensitivity and suppresses neuroinflammation in CCI rats by up-regulating miR-1249-3p, directly targeting and inhibiting VEGFA, and thereby suppressing the NF-κB signaling. SUPPLEMENTARY MATERIALS Supplementary materials can be found via https://doi.org/10.3344/kjp.25449. Footnotes DATA AVAILABILITY The datasets supporting the finding of this study are available from the corresponding author upon reasonable request. CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported. FUNDING This study was funded by Guangdong Provincial Health and Wellness Appropriate Technology Promotion Project (2023032615074255). AUTHOR CONTRIBUTIONS Hailin Zhao: Study conception, Methodology, Supervision, Funding acquisition; Chuping Peng: Writing/manuscript preparation, Critical review, Commentary or revision; Xiumei Zhu: Methodology, Formal analysis; Long Wang: Methodology, Formal analysis, Data curation; Lu Ye: Study conception, Methodology, Formal analysis, Writing/manuscript preparation, Critical review, Commentary or revision. REFERENCES Associated Data Supplementary Materials